Due to some unique aspects of the EU Cosmetics Regulation compared to other EU product safety regulations, the cosmetics industry has been particularly impacted by Brexit. Given that Brexit has now taken place, it is timely to reconsider this ongoing impact on industry and provide some guidance on forward-looking planning.
On 18 February 2020, the UK’s Medicines and Healthcare products Regulatory Agency (MHRA), updated its guidance on medicine licensing post-Brexit “Apply for a licence to market a medicine in the UK”. The update provides further clarity on the UK’s status in the licensing process now that Brexit has taken place.
The Office for Product Safety and Standards (OPSS) has published additional detailed guides for business on specific product safety regulations in the event of a No Deal Brexit.
On 12 July 2018, the UK government published a White Paper outlining its proposals for the future relationship between the United Kingdom and European Union. What implications does the White Paper have for product manufacturers?